AngioDynamics sees lower sales, revenues beat analysts' expectations; Angiotech sells certain Quill IP rights to Ethicon;

@FierceMedDev: Another take: MD+DI Editor Says Consumer Reports Article on Dangerous Devices is Dangerous Reporting. Item | Follow @FierceMedDev

> AngioDynamics ($ANGO) reported a Q3 loss, much of which it blamed on lower sales, particularly in the U.S. On the bright side, adjusted earnings and revenues came in above analysts' expectations. Article

> Angiotech Pharmaceuticals ($ANPI) has sold certain Quill intellectual property to Johnson & Johnson's ($JNJ) Ethicon unit. Angiotech will receive $20 million upfront and up to an additional $42 million in contingent cash consideration. Angiotech release

> GenMark Diagnostics ($GNMK) and Advanced Liquid Logic (ALL) will collaborate to develop an all-electronic, fully integrated in vitro diagnostic platform. The platform will wed ALL's proprietary electrowetting technology and GenMark's proprietary electrochemical detection. GenMark release

> Delcath Systems ($DCTH) has scored CE Mark approval for the second generation hemofiltration cartridge of its Hepatic CHEMOSAT delivery system. Doctors will be able to use the product for the percutaneous intra-arterial administration of melphalan hydrochloride to the liver of patients who may benefit from such treatment. Delcath release

> Salt Lake City-based Amedica will begin distribution of Dynamic Bone and BioDfence DryFlex. These new allograft products will provide surgeons with solutions for their patients and expand the Origin Orthobiologics line of products. Amedica release

And Finally... Johnson & Johnson may have been stung by repeated recalls and ongoing litigation, but consumers still are rating it highly. Results from an online survey of 10,000 people conducted by Reputation Institute found the company ranked third most reputable. Participants were asked about their immediate reactions to 150 companies, and Medtronic ($MDT) and Abbott Labs ($ABT) also fared well. Story